PKM2 Regulates Hepatocellular Carcinoma Cell Epithelial-mesenchymal Transition and Migration upon EGFR Activation |
Fan, Fang-Tian
(Department of Pharmacology, College of Pharmacy, Nanjing University of Chinese Medicine)
Shen, Cun-Si (Department of Pharmacology, College of Pharmacy, Nanjing University of Chinese Medicine) Tao, Li (Department of Pharmacology, College of Pharmacy, Nanjing University of Chinese Medicine) Tian, Chao (Department of Pharmacology, College of Pharmacy, Nanjing University of Chinese Medicine) Liu, Zhao-Guo (Department of Pharmacology, College of Pharmacy, Nanjing University of Chinese Medicine) Zhu, Zhi-Jie (Department of Pharmacology, College of Pharmacy, Nanjing University of Chinese Medicine) Liu, Yu-Ping (Department of Pharmacology, College of Pharmacy, Nanjing University of Chinese Medicine) Pei, Chang-Song (Department of Pharmacology, College of Pharmacy, Nanjing University of Chinese Medicine) Wu, Hong-Yan (Department of Pharmacology, College of Pharmacy, Nanjing University of Chinese Medicine) Zhang, Lei (Department of Pharmacology, College of Pharmacy, Nanjing University of Chinese Medicine) Wang, Ai-Yun (Department of Pharmacology, College of Pharmacy, Nanjing University of Chinese Medicine) Zheng, Shi-Zhong (Department of Pharmacology, College of Pharmacy, Nanjing University of Chinese Medicine) Huang, Shi-Le (Feist-Weiller Cancer Center, Louisiana State University Health Sciences Center Shreveport) Lu, Yin (Department of Pharmacology, College of Pharmacy, Nanjing University of Chinese Medicine) |
1 | Yang W, Zheng Y, Xia Y, et al (2012). ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect. Nat Cell Biol, 14, 1295-304. DOI ScienceOn |
2 | Wong N, De Melo J, Tang D (2013). PKM2, a Central Point of Regulation in Cancer Metabolism. Int J Cell Biol, 2013, 242513. |
3 | Xu Z, Shen MX, Ma DZ, et al (2003). TGF-beta1-promoted epithelial-to-mesenchymal transformation and cell adhesion contribute to TGF-beta1-enhanced cell migration in SMMC-7721 cells. Cell Res, 13, 343-50. DOI ScienceOn |
4 | Yang W, Xia Y, Ji H, et al (2011). Nuclear PKM2 regulates beta-catenin transactivation upon EGFR activation. Nature, 480, 118-22. |
5 | Zhang Q, Bai X, Chen W, et al (2013). Wnt/beta-catenin signaling enhances hypoxia-induced epithelial-mesenchymal transition in hepatocellular carcinoma via crosstalk with hif-1alpha signaling. Carcinogenesis.??? |
6 | Zhou CF, Li XB, Sun H, et al (2012a). Pyruvate kinase type M2 is upregulated in colorectal cancer and promotes proliferation and migration of colon cancer cells. IUBMB Life, 64, 775-82. DOI |
7 | Zhou L, Liu C, Meng FD, et al (2012b). Long-term prognosis in hepatocellular carcinoma patients after hepatectomy. Asian Pac J Cancer Prev, 13, 483-6. 과학기술학회마을 DOI ScienceOn |
8 | Zhu WJ, Huang CY, Li C, et al (2013). Risk factors for early recurrence of hbv-related hepatocellular carcinoma meeting milan criteria after curative resection. Asian Pac J Cancer Prev, 14, 7101-6. 과학기술학회마을 DOI ScienceOn |
9 | Spoden GA, Rostek U, Lechner S, et al (2009). Pyruvate kinase isoenzyme M2 is a glycolytic sensor differentially regulating cell proliferation, cell size and apoptotic cell death dependent on glucose supply. Exp Cell Res, 315, 2765-74. DOI ScienceOn |
10 | Ogunwobi OO, Liu C (2011). Hepatocyte growth factor upregulation promotes carcinogenesis and epithelialmesenchymal transition in hepatocellular carcinoma via Akt and COX-2 pathways. Clin Exp Metastasis, 28, 721-31. DOI |
11 | Pan FY, Zhang SZ, Xu N, et al (2010). Beta-catenin signaling involves HGF-enhanced HepG2 scattering through activating MMP-7 transcription. Histochem Cell Biol, 134, 285-95. DOI |
12 | Personeni N, Rimassa L, Santoro A (2012). Biomarkers in hepatocellular carcinoma--letter. Clin Cancer Res, 18, 4861. DOI ScienceOn |
13 | Tamada M, Suematsu M, Saya H (2012). Pyruvate kinase m2: multiple faces for conferring benefits on cancer cells. Clin Cancer Res, 18, 5554-61. DOI ScienceOn |
14 | Tan X, Apte U, Micsenyi A, et al (2005). Epidermal growth factor receptor: a novel target of the Wnt/beta-catenin pathway in liver. Gastroenterology, 129, 285-302. DOI ScienceOn |
15 | Tanaka M, Masaki Y, Tanaka K, et al (2013). Reduction of fatty acid oxidation and responses to hypoxia correlate with the progression of de-differentiation in HCC. Mol Med Rep, 7, 365-70. |
16 | Tsuji T, Ibaragi S, Hu GF (2009). Epithelial-mesenchymal transition and cell cooperativity in metastasis. Cancer Res, 69, 7135-9. DOI ScienceOn |
17 | Wang LY, Liu YP, Chen LG, et al (2013). Pyruvate kinase M2 plays a dual role on regulation of the EGF/EGFR signaling via E-cadherin-dependent manner in gastric cancer cells. PLoS One, 8, e67542. DOI |
18 | Liu D, Aguirre Ghiso J, Estrada Y, Ossowski L (2002). EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma. Cancer Cell, 1, 445-57. DOI ScienceOn |
19 | Wiangnon S, Kamsa-ard S, Suwanrungruang K, et al (2012). Trends in incidence of hepatocellular carcinoma, 1990-2009, Khon Kaen, Thailand. Asian Pac J Cancer Prev, 13, 1065-8. 과학기술학회마을 DOI ScienceOn |
20 | Luo W, Hu H, Chang R, et al (2011a). Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell, 145, 732-44. DOI ScienceOn |
21 | Llovet JM, Bruix J (2008). Molecular targeted therapies in hepatocellular carcinoma. Hepatology, 48, 1312-27. DOI ScienceOn |
22 | Lu Z, Ghosh S, Wang Z, Hunter T (2003). Downregulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of beta-catenin, and enhanced tumor cell invasion. Cancer Cell, 4, 499-515. DOI ScienceOn |
23 | Luo W, Semenza GL (2011b). Pyruvate kinase M2 regulates glucose metabolism by functioning as a coactivator for hypoxia-inducible factor 1 in cancer cells. Oncotarget, 2, 551-6. |
24 | Macintyre AN, Rathmell JC (2011). PKM2 and the tricky balance of growth and energy in cancer. Mol Cell, 42, 713-4. DOI ScienceOn |
25 | Maheswaran T, Rushbrook SM (2012). Epithelial-mesenchymal transition and the liver: role in hepatocellular carcinoma and liver fibrosis. J Gastroenterol Hepatol, 27, 418-20. DOI ScienceOn |
26 | Mittal S, El-Serag HB (2013). Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol, 47 Suppl, S2-6. DOI |
27 | Fang D, Hawke D, Zheng Y, et al (2007). Phosphorylation of beta-catenin by AKT promotes beta-catenin transcriptional activity. J Biol Chem, 282, 11221-9. DOI ScienceOn |
28 | Nejak-Bowen KN, Monga SP (2011). Beta-catenin signaling, liver regeneration and hepatocellular cancer: sorting the good from the bad. Semin Cancer Biol, 21, 44-58. DOI ScienceOn |
29 | Norsa'adah B, Nurhazalini-Zayani CG (2013). Epidemiology and survival of hepatocellular carcinoma in north-east Peninsular Malaysia. Asian Pac J Cancer Prev, 14, 6955-9. 과학기술학회마을 DOI ScienceOn |
30 | Eggert T, McGlynn KA, Duffy A, et al (2013). Epidemiology of fibrolamellar hepatocellular carcinoma in the USA, 2000-10. Gut. |
31 | Fischer AN, Fuchs E, Mikula M, et al (2007). PDGF essentially links TGF-beta signaling to nuclear beta-catenin accumulation in hepatocellular carcinoma progression. Oncogene, 26, 3395-405. DOI ScienceOn |
32 | Guan CN, Chen XM, Lou HQ, et al (2012). Clinical significance of axin and beta-catenin protein expression in primary hepatocellular carcinomas. Asian Pac J Cancer Prev, 13, 677-81. 과학기술학회마을 DOI ScienceOn |
33 | Guarino M (2007). Epithelial-mesenchymal transition and tumour invasion. Int J Biochem Cell Biol, 39, 2153-60. DOI ScienceOn |
34 | Hu T, Li C (2010). Convergence between Wnt-beta-catenin and EGFR signaling in cancer. Mol Cancer, 9, 236. |
35 | Ji H, Wang J, Nika H, et al (2009). EGF-induced ERK activation promotes CK2-mediated disassociation of alpha-catenin from beta-catenin and transactivation of beta-catenin. Mol Cell, 36, 547-59. DOI ScienceOn |
36 | Al Moustafa AE, Achkhar A, Yasmeen A (2012). EGF-receptor signaling and epithelial-mesenchymal transition in human carcinomas. Front Biosci (Schol Ed), 4, 671-84. |
37 | Lee J, Kim HK, Han YM, Kim J (2008). Pyruvate kinase isozyme type M2 (PKM2) interacts and cooperates with Oct-4 in regulating transcription. Int J Biochem Cell Biol, 40, 1043-54. DOI ScienceOn |
38 | Li SH, Guo ZX, Xiao CZ, et al (2013). Risk factors for early and late intrahepatic recurrence in patients with single hepatocellular carcinoma without macrovascular invasion after curative resection. Asian Pac J Cancer Prev, 14, 4759-63. 과학기술학회마을 DOI ScienceOn |
39 | Cano A, Perez-Moreno MA, Rodrigo I, et al (2000). The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol, 2, 76-83. DOI ScienceOn |
40 | Altekruse SF, McGlynn KA, Dickie LA, Kleiner DE (2012). Hepatocellular carcinoma confirmation, treatment, and survival in surveillance, epidemiology, and end results registries, 1992-2008. Hepatology, 55, 476-82. DOI ScienceOn |
41 | Buckley AF, Burgart LJ, Sahai V, Kakar S (2008). Epidermal growth factor receptor expression and gene copy number in conventional hepatocellular carcinoma. Am J Clin Pathol, 129, 245-51. DOI ScienceOn |
42 | Eastham AM, Spencer H, Soncin F, et al (2007). Epithelialmesenchymal transition events during human embryonic stem cell differentiation. Cancer Res, 67, 11254-62. DOI ScienceOn |
43 | Gao X, Wang H, Yang JJ, et al (2012). Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase. Mol Cell, 45, 598-609. DOI ScienceOn |
![]() |